ABOUT US

We are pioneers in exosome-based liquid biopsy, empowered by nano-fabrication technologies, and fueled by our foresight and curiosity about biology, data analytics and machine learning

WE ENSURE LIFELONG HEALTH FOR EVERYONE

Our mission is to detect cancer in the earliest stages using urine. Our core technology is the unique nanowire device capable of extracting 99% of exosomes, known for their deep relationship with diseases, making them promising biomarkers. We will provide accurate and unpainful early cancer detection method to create a society where everyone can stay healthy throughout their lifetime.

TEAM

LEADERSHIP

Ryuichi Onose

Chief Executive Officer (CEO) & Co-Founder

Yasui Takao, Ph.D.

Scientific Advisor & Co-Founder

Yuki Ichikawa, Ph.D.

Chief Technology Officer (CTO)

Ryuichi Onose

Ryuichi Onose, the co-founder of our company in May 2018, has served as CEO since incorporation. Prior to co-founding our company, Ryuichi served in Mitsubishi Corp. From 2014 to 2018 and engaged in project management & finance of LNG vessels. Additionally, Ryuichi founded a private residence management company in 2016 and spread the service nationwide. Ryuichi graduated Waseda University in Japan and studied abroad in McGill Univ. in Canada.
Ryuichi has been selected as 2021 Forbes 30 Under 30 in Healthcare & Science.

Yasui Takao, Ph.D.

Yasui Takao, Ph.D., the co-founder of our company in May 2018, has served as Scientific Advisor since incorporation. Takao also serves as an associate professor at Department of Biomolecular Engineering, Nagoya University since 2018. Takao’s research interests are focused on designing, fabricating, and characterizing nanospace for applications in healthcare, diagnosis, sensing biomolecules, and engineering biology.

Yuki Ichikawa, Ph.D.

Yuki Ichikawa has served as our CTO since January 2019.
After receiving a Ph.D. degree in Chemical Biology at Graduate School of Pharmaceutical Sciences, the University of Tokyo, Yuki worked as a Sales and Marketing Manager for pharmaceutical products at Bayer from 2013 to 2018. Additionally, Yuki has experience in supporting to introduce medical technology to developing countries in a US-based NPO.

Mika Mizunuma, Ph.D.

Chief Operating Officer (COO)

Mika Mizunuma, Ph.D.

Mika Mizunuma has served as our COO since October 2019.
She received a B.A., in pharmaceutical sciences from Kyoto University, and a Ph.D. from the University of Tokyo. From 2013 to 2014, she worked at AstraZeneca and engaged in new product launch and developing medical strategy. From 2014 to 2017, she worked at McKinsey & Company and engaged in developing new business strategy and product strategy in healthcare field. Afterwards, she founded digital health company, Watashikampo, and launched an online pharmacy service.

Ryuichi Onose

Chief Executive Officer (CEO) & Co-Founder

Ryuichi Onose

Ryuichi Onose, the co-founder of our company in May 2018, has served as CEO since incorporation. Prior to co-founding our company, Ryuichi served in Mitsubishi Corp. From 2014 to 2018 and engaged in project management & finance of LNG vessels. Additionally, Ryuichi founded a private residence management company in 2016 and spread the service nationwide. Ryuichi graduated Waseda University in Japan and studied abroad in McGill Univ. in Canada.
Ryuichi has been selected as 2021 Forbes 30 Under 30 in Healthcare & Science.

Yasui Takao, Ph.D.

Scientific Advisor & Co-Founder

Yasui Takao, Ph.D.

Yasui Takao, Ph.D., the co-founder of our company in May 2018, has served as Scientific Advisor since incorporation. Takao also serves as an associate professor at Department of Biomolecular Engineering, Nagoya University since 2018. Takao’s research interests are focused on designing, fabricating, and characterizing nanospace for applications in healthcare, diagnosis, sensing biomolecules, and engineering biology.

Yuki Ichikawa, Ph.D.

Chief Technology Officer (CTO)

Yuki Ichikawa, Ph.D.

Yuki Ichikawa has served as our CTO since January 2019.
After receiving a Ph.D. degree in Chemical Biology at Graduate School of Pharmaceutical Sciences, the University of Tokyo, Yuki worked as a Sales and Marketing Manager for pharmaceutical products at Bayer from 2013 to 2018. Additionally, Yuki has experience in supporting to introduce medical technology to developing countries in a US-based NPO.

Mika Mizunuma, Ph.D.

Chief Operating Officer (COO)

Mika Mizunuma, Ph.D.

Mika Mizunuma has served as our COO since October 2019.
She received a B.A., in pharmaceutical sciences from Kyoto University, and a Ph.D. from the University of Tokyo. From 2013 to 2014, she worked at AstraZeneca and engaged in new product launch and developing medical strategy. From 2014 to 2017, she worked at McKinsey & Company and engaged in developing new business strategy and product strategy in healthcare field. Afterwards, she founded digital health company, Watashikampo, and launched an online pharmacy service.

SCIENTIFIC ADVISORS

Masatoshi Wakui, MD, Ph.D.

Clinical Advisor

Yoshinobu Baba, Ph.D.

Technology Advisor, Professor

Takashi Washio, Ph.D.

Machine Learning Advisor, Professor

Masatoshi Wakui, MD, Ph.D.

2001 Research Fellow, Department of arthritis and clinical immunology at University of Florida.
2009 Assistant Professor of department of Laboratory Medicine, Keio University.
2017 Assistant Professor of department of Laboratory Medicine, Keio University and Chief Doctor of department of Laboratory Medicine, Keio University Hospital.
2020 Present Associate Professor of department of Laboratory Medicine, Keio University and Chief Doctor of department of Laboratory Medicine, Keio University Hospital.

Yoshinobu Baba, Ph.D.

2004 Professor of Department of Biomolecular Engineering, Graduate School of Engineering at Nagoya University.
2010 Adviser of Health Research Institute, AIST.
2017 Managing Director, Research of “Extracellular Fine Particles” at CREST of JST.
Received over 85 awards for contributions in nanobiotechnology.

Takashi Washio, Ph.D.

Expert of Machine Learning, Professor received a Ph.D. from Graduate School of Nuclear Engineering, Tohoku University.
1988 Visiting researcher of Massachusetts Institute of Technology.
1994 Principal investigator of Mitsubishi Research Institute, Inc
2006 - Present Professor of The Institute of Scientific and Industrial Research, Osaka Univ.
2006 - Present Professor of The Institute of Statistical Mathematics, Osaka Univ.

Takeshi Akatsu, Ph.D.

Patent Attorney, Professor

Akira Yokoi, MD, Ph.D.

Department of Gynecology

Takeshi Akatsu, Ph.D.

He received a Ph.D. from Graduate School of Engineering, The University of Tokyo.
Studied at University of California at Santa Barbara, Researched at Max-Planck-Institut für Metallforschung in Germany.
2002 Project leader of R&D Department, SOITEC in France.
2008 Worked in some patent firms in Japan.
2014 Joined Quantum Biosystems as a Director of IP.
Cofounder of medical start-up Specialize in materials engineering, electron and bio devices.
Proficient in English, German and French. Patent attorney.

Akira Yokoi, MD, Ph.D.

2009 Doctor, Nagoya First Red Cross Hospital
2014 Research Scientist, National Cancer Center, Japan
2018 Postdoctoral Fellow, The University of Texas MD Anderson Cancer Center
2020 Assistant Professor, Department of Obstetrics and Gynecology, Nagoya University Hospital
2020 Assistant Professor, Nagoya University Graduate School of Advanced Studies

Awards
Nagoya University Academic Encouragement Award (2017)
FWC-SGO Clovis Oncology Post-Doctoral Award (2019)
Japanese Cancer Association Encouragement Award (2020)

Masatoshi Wakui, MD, Ph.D.

Clinical Advisor

Masatoshi Wakui, MD, Ph.D.

2001 Research Fellow, Department of arthritis and clinical immunology at University of Florida.
2009 Assistant Professor of department of Laboratory Medicine, Keio University.
2017 Assistant Professor of department of Laboratory Medicine, Keio University and Chief Doctor of department of Laboratory Medicine, Keio University Hospital.
2020 Present Associate Professor of department of Laboratory Medicine, Keio University and Chief Doctor of department of Laboratory Medicine, Keio University Hospital.

Yoshinobu Baba, Ph.D.

Technology Advisor, Professor

Yoshinobu Baba, Ph.D.

2004 Professor of Department of Biomolecular Engineering, Graduate School of Engineering at Nagoya University.
2010 Adviser of Health Research Institute, AIST.
2017 Managing Director, Research of “Extracellular Fine Particles” at CREST of JST.
Received over 85 awards for contributions in nanobiotechnology.

Takashi Washio, Ph.D.

Machine Learning Advisor, Professor

Takashi Washio, Ph.D.

Expert of Machine Learning, Professor received a Ph.D. from Graduate School of Nuclear Engineering, Tohoku University.
1988 Visiting researcher of Massachusetts Institute of Technology.
1994 Principal investigator of Mitsubishi Research Institute, Inc
2006 - Present Professor of The Institute of Scientific and Industrial Research, Osaka Univ.
2006 - Present Professor of The Institute of Statistical Mathematics, Osaka Univ.

Takeshi Akatsu, Ph.D.

Patent Attorney, Professor

Takeshi Akatsu, Ph.D.

He received a Ph.D. from Graduate School of Engineering, The University of Tokyo.
Studied at University of California at Santa Barbara, Researched at Max-Planck-Institut für Metallforschung in Germany.
2002 Project leader of R&D Department, SOITEC in France.
2008 Worked in some patent firms in Japan.
2014 Joined Quantum Biosystems as a Director of IP.
Cofounder of medical start-up Specialize in materials engineering, electron and bio devices.
Proficient in English, German and French. Patent attorney.

Akira Yokoi, MD, Ph.D.

Department of Gynecology

Akira Yokoi, MD, Ph.D.

2009 Doctor, Nagoya First Red Cross Hospital
2014 Research Scientist, National Cancer Center, Japan
2018 Postdoctoral Fellow, The University of Texas MD Anderson Cancer Center
2020 Assistant Professor, Department of Obstetrics and Gynecology, Nagoya University Hospital
2020 Assistant Professor, Nagoya University Graduate School of Advanced Studies

Awards
Nagoya University Academic Encouragement Award (2017)
FWC-SGO Clovis Oncology Post-Doctoral Award (2019)
Japanese Cancer Association Encouragement Award (2020)

INVESTORS

ANRI
Daiwa Corporate Investment Co.,Ltd.
Aflac Ventures LLC
Japan Science and Technology Agency (JST)
FF APAC Scout
MORI TRUST CO., LTD.

OFFICES

MEDIA

  • 週刊東洋経済
  • 週刊ダイヤモンド
  • NIKKEI STYLE
  • Forbes JAPAN
  • TRENDY 日経トレンディ
  • NIKKEI Business Daily 日経産業新聞
  • Tech Crunch
  • 日経バイオテク
  • 日本経済新聞